Significance of lymphocyte counts at diagnosis in the management of ITP: the relationship between lymphocyte counts and treatment success in H. pylori-infected patients

International Journal of Hematology

Volumn 101, Issue 3, 2015, Pages 268-272

  Nagata, Akihisa ^a   Sekiguchi, Naohiro ^a   Kurimoto, Miwa ^a   Noto, Satoshi ^a   Takezako, Naoki ^a  

^a NATIONAL HOSPITAL ORGANIZATION DISASTER MEDICAL CENTER   (Japan)

Author keywords

Eradication; H. pylori; Initial; ITP; Lymphocyte; Response

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT OUTCOME; COMPLICATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; LYMPHOCYTE; MICROBIOLOGY; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925488096     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1737-9     Document Type: Article

References (30)

1. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133:364–74.
2. Emilia G, Luppi M, Zucchini P, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood. 2007;110:3833–41.
3. Franchini M, Vescovi PP, Garofano M, Veneri D. Helicobacter pylori-associated idiopathic thrombocytopenic purpura: a narrative review. Semin Thromb Hemost. 2012;38:463–8.
4. Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematol Am Soc Hematol Educ Progr. 2012;2012:306–12.
5. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113:1231–40.
6. Arnold DM, Bernotas A, Nazi I, et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94:850–6.
7. Franchini M, Veneri D. Helicobacter pylori infection and immunethrombocytopenic purpura. Haematologica. 2003;88:1087–91.
8. Takezako N, Sekiguchi N, Tanimura A, Homma C, et al. Lymphocytosis in idiopathic thrombocytopenic purpura patients infected by Helicobacter pylori. Open J Blood Dis. 2013;3:32–5.
9. McCrae KR, Bussel JB, et al. Platelets: an update on diagnosis and management of thrombocytopenic disorders. Hematol Am Soc Hematol Educ Progr. 2001;2001:282–305.
10. Satoh K. Indications for Helicobacter pylori eradication therapy and first-line therapy regimen in Japan: recommendation by the Japanese Society for Helicobacter Research. J Gastroenterol. 2002;37(Suppl 13):34–8.
11. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
12. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–86.
13. Ohe M, Kohno M. Three cases of idiopathic thrombocytopenic purpura showing an increase in the platelet count following clarithromycin treatment. Rinsho Ketsueki. 2003;44:1044–6.
14. Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;352:878.
15. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.
16. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574–96.
17. Neunert C, Lim W, Crowther M, American Society of Hematology, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–207.
18. Franchini M. Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection. Med Hypotheses. 2005;65:1128–31.
19. Shirasugi Y, Ando K, Miyazaki K, et al. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol. 2012;95:652–9.
20. Asahi A, Kuwana M, Suzuki H, et al. Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica. 2006;91:1436–7.
21. Ando T, Tsuzuki T, Mizuno T, et al. Characteristics of Helicobacter pylori-induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter. 2004;9:443–52.
22. Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2001;115:1002–3.
23. Michel M, Cooper N, Jean C, et al. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood. 2004;103:890–6.
24. Čulić O, Eraković V, et al. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429:209–29.
25. Yamanishi S, Iizumi T, Watanabe E, et al. Implications for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori urease. Infect Immun. 2006;74:248–56.
26. Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103:2645–7.
27. Wang T, Zhao H, Ren H, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica. 2005;90:914–23.
28. Olsson B, Andersson PO, Jernås M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–4.
29. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119:1356–62.
30. Arnold DM. Positioning new treatments in the management of immune thrombocytopenia. Pediatr Blood Cancer. 2013;60(Suppl 1):S19–22.